Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration. The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate at study entry, and a 100% tumour control […]
